Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases-Reference-Cited by-同舟云学术

Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases

Published:2016-04 Issue:4 Volume:14 Page:550-557.e2
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Ungar Bella,Levy Idan,Yavne Yarden,Yavzori Miri,Picard Orit,Fudim Ella,Loebstein Ronen,Chowers Yehuda,Eliakim Rami,Kopylov Uri,Ben-Horin Shomron

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference30 articles.

1. Results of the 2nd scientific workshop of the ECCO (IV): therapeutic strategies to enhance intestinal healing in inflammatory bowel disease;Armuzzi;J Crohns Colitis,2012

2. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease;Schnitzler;Inflamm Bowel Dis,2009

3. Rate and predictors of mucosal healing in patients with inflammatory bowel disease treated with anti-TNF-alpha antibodies;Beigel;PloS One,2014

4. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis;Colombel;Gastroenterology,2011

5. Infliximab for induction and maintenance therapy for ulcerative colitis;Rutgeerts;N Eng J Med,2005

Cited by 329 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetically engineered bacteria as inflammatory bowel disease therapeutics;Engineering Microbiology;2024-12

2. An in situ bioadhesive foam as a large intestinal delivery platform for antibody fragment to treat inflammatory bowel disease;Journal of Controlled Release;2024-10

3. Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study;BioDrugs;2024-08-22

4. Effectiveness of Switching to Subcutaneous Infliximab in Ulcerative Colitis Patients Experiencing Intravenous Infliximab Failure;Gut and Liver;2024-06-05

5. Fluorescence-Based Lateral Flow Immunoassay for Quantification of Infliximab: Analytical and Clinical Performance Evaluation;Therapeutic Drug Monitoring;2024-05-15